ArticleJournal of translational medicine2024
USP13 ameliorates nonalcoholic fatty liver disease through inhibiting the activation of TAK1.
Min Tang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it